{"nctId":"NCT03057951","briefTitle":"EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)","startDateStruct":{"date":"2017-03-02","type":"ACTUAL"},"conditions":["Heart Failure"],"count":5988,"armGroups":[{"label":"10 mg Empagliflozin","type":"EXPERIMENTAL","interventionNames":["Drug: Empagliflozin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Empagliflozin","otherNames":["JARDIANCE, JARDIANZ, GIBTULIO"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Male or female patient, age \\>= 18 years at screening. For Japan only: Age \\>=20 years at screening\n* Patients with chronic HF (Chronic Heart Failure) NYHA (New York Heart Association classification) class II-IV and preserved EF (Ejection Fraction)(LVEF (Left Ventricular Ejection Fraction) \\> 40 %) and elevated NT-proBNP (N-terminal of the prohormone brain natriuretic peptide) \\> 300 pg/ml for patients without AF, OR \\> 900 pg/ml for patients with AF, analysed at the Central laboratory at Visit 1\n* Structural heart disease within 6 months prior to Visit 1, OR documented HHF (Hospitalisation for Heart Failure) within 12 months prior to Visit 1\n* Stable dose of oral diuretics, if prescribed\n* Signed and dated written ICF (informed consent form)\n* Further inclusion criteria apply\n\nExclusion criteria:\n\n* Myocardial infarction, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA (Transient Ischaemic Attack) in past 90 days prior to Visit 1\n* Heart transplant recipient or listed for heart transplant\n* Acute decompensated HF (Heart Failure)\n* Systolic blood pressure (SBP) \\>= 180 mmHg at Visit 2.\n* Symptomatic hypotension and/or a SBP \\< 100 mmHg\n* Indication of liver disease,\n* Impaired renal function, defined as eGFR (Estimated Glomerular Filtration Rate) \\< 20 mL/min/1.73 m2 (CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration Equation))cr or requiring dialysis\n* History of ketoacidosis\n* Current use or prior use of a SGLT (Sodium-glucose co-transporter) -2 inhibitor or combined SGLT-1 and 2 inhibitor\n* Currently enrolled in another investigational device or drug trial\n* Known allergy or hypersensitivity to empagliflozin or other SGLT-2 inhibitors\n* Women who are pregnant, nursing, or who plan to become pregnant while in the trial\n* Further exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF)","description":"Failure with preserved Ejection Fraction (HFpEF). The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed:\n\nIncidence rate per 100 pt-yrs = 100 \\* number of patients with event / time at risk \\[years\\].\n\nTime at risk \\[years\\] = Sum of time at risk \\[days\\] over all patients in a treatment group / 365.25.\n\nPatients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.67","spread":null},{"groupId":"OG001","value":"6.86","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of Adjudicated Hospitalisation for Heart Failure (HHF) (First and Recurrent)","description":"Reported is the total number of adjudicated HHF events (first and recurrent) which occurred.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"541","spread":null},{"groupId":"OG001","value":"407","spread":null}]}]}]},{"type":"SECONDARY","title":"eGFR (CKD-EPI) cr Slope of Change From Baseline","description":"Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR(CKD-EPI)cr) slope of change from baseline.\n\nAvailable on-treatment change-from-baseline data were used. The slope represents the long term effect of eGFR change from baseline and provides the yearly rate of decline.\n\nTimepoints after baseline were included in calculation of slope of change from baseline.\n\nThe slope per patient was calculated using a random coefficient model with terms for treatment, region, baseline status of diabetes, age, sex, left ventricular ejection fraction (LVEF) and glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula (eGFR (CKD-EPI)cr) at baseline and in addition the factors \"time\", \"treatment-by-time interaction\", and \"baseline eGFR (CKD-EPI)cr-by-time interaction\".","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.616","spread":"0.108"},{"groupId":"OG001","value":"-1.253","spread":"0.108"}]}]}]},{"type":"SECONDARY","title":"Time to the First Event in the Composite Renal Endpoint: Chronic Dialysis, Renal Transplant, or Sustained Reduction in eGFR (CKD-EPI)cr","description":"Chronic dialysis was defined as dialysis with a frequency of twice per week or more for at least 90 days.\n\nSustained was determined by two or more consecutive post-baseline central laboratory measurement separated by at least 30 days.\n\nReduction in glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr) was defined as reduction in eGFR from baseline ≥40%, eGFR \\<15 mL/min/1.73 m\\^2 for patients with baseline eGFR ≥30 mL/min/1.73 m\\^2, or eGFR \\<10 mL/min/1.73 m\\^2 for patients with baseline eGFR \\<30 mL/min/1.73 m\\^2.\n\nThe incidence rate per 100 patient years (100 \\* number of patients with event / time at risk \\[years\\]) is reported. Time at risk \\[year\\] is calculated as: Sum of time at risk \\[days\\] over all patients in a treatment group / 365.25.\n\nAbbreviation:\n\nPatient-years (pt-yrs).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":null},{"groupId":"OG001","value":"2.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Adjudicated Hospitalisation for Heart Failure (HHF)","description":"Time to first adjudicated HHF. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed:\n\nIncidence rate per 100 pt-yrs = 100 \\* number of patients with event / time at risk \\[years\\].\n\nTime at risk \\[years\\] = Sum of time at risk \\[days\\] over all patients in a treatment group / 365.25.\n\nPatients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.97","spread":null},{"groupId":"OG001","value":"4.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Adjudicated Cardiovascular (CV) Death","description":"Time to adjudicated CV death. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed:\n\nIncidence rate per 100 pt-yrs = 100 \\* number of patients with event / time at risk \\[years\\].\n\nTime at risk \\[years\\] = Sum of time at risk \\[days\\] over all patients in a treatment group / 365.25.\n\nPatients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.81","spread":null},{"groupId":"OG001","value":"3.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to All-cause Mortality","description":"Time to all-cause mortality. The incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed:\n\nIncidence rate per 100 pt-yrs = 100 \\* number of patients with event / time at risk \\[years\\].\n\nTime at risk \\[years\\] = Sum of time at risk \\[days\\] over all patients in a treatment group / 365.25.\n\nPatients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":null},{"groupId":"OG001","value":"6.60","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Onset of Diabetes Mellitus (DM) in Patients With Pre-DM","description":"Time to onset of DM (defined as HbA1c ≥6.5% or as diagnosed by the investigator) in patients with pre-DM.\n\nPre-DM was defined as no history of DM and no HbA1c ≥6.5% before treatment, and a pre-treatment HbA1c value of ≥5.7% and \\<6.5%.\n\nThe incidence rate per 100 patient years (pt-yrs) is presented and calculated as followed:\n\nIncidence rate per 100 pt-yrs = 100 \\* number of patients with event / time at risk \\[years\\].\n\nTime at risk \\[years\\] = Sum of time at risk \\[days\\] over all patients in a treatment group / 365.25.\n\nPatients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.39","spread":null},{"groupId":"OG001","value":"6.12","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Kansas City Cardiomyopathy Questionaire (KCCQ) Clinical Summary Score at Week 52","description":"The KCCQ is a 23-item self-administered questionnaire designed to evaluate physical limitations, symptoms (frequency, severity, and changes over time), social limitations, self-efficacy, and quality of life in patients with Heart Failure. The KCCQ-clinical summary score comprises the following domains: Symptom frequency, symptom burden and physical limitation. The score is calculated by summing domain responses and then transforming scores to a 0-100 unit scale with higher scores indicating better health status.\n\nFor patients who died, a worst score (score of 0) was imputed for the score at all subsequent scheduled visits after the date of death where the score would have been assessed.\n\nChange from baseline in KCCQ-score at week 52 was modeled using a MMRM with visit (week 12, 32 and 52) as repeated measures, adjusted mean (standard error) at week 52 is reported.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.18","spread":"0.31"},{"groupId":"OG001","value":"4.51","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Occurrence of All-cause Hospitalisation (First and Recurrent)","description":"Occurrence of all-cause hospitalisation (first and recurrent). Total number of all cause hospitalisations is reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2769","spread":null},{"groupId":"OG001","value":"2566","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1543,"n":2989},"commonTop":["Hypertension","Hypotension","Fall","Urinary tract infection","Hyperkalaemia"]}}}